Claims
- 1. An adrenomedullin (ADM) agonist 7-25 amino acids in length, wherein said ADM agonist comprises a fraction or the entirety of the amino acid sequence ADM(32-40).
- 2. The ADM agonist of claim 1, wherein said ADM agonist is 9-25 amino acids in length and comprises the amino acid sequence ADM(32-40).
- 3. The ADM agonist of claim 1, wherein the carboxyl terminus is amidated.
- 4. The ADM agonist of claim 2, wherein the carboxyl terminus is amidated.
- 5. The ADM agonist of claim 2, wherein said ADM agonist comprises the amino acid sequence ADM(28-40).
- 6. The ADM agonist of claim 2, wherein said ADM agonist comprises the amino acid sequence ADM(32-52).
- 7. The ADM agonist of claim 2, wherein said ADM agonist comprises the amino acid sequence ADM(30-52).
- 8. A pharmaceutical composition comprising the ADM agonist of claim 1.
- 9. A pharmaceutical composition comprising the ADM agonist of claim 2.
- 10. A method of promoting bone growth in a patient, said method comprising administering to a patient in need thereof an ADM agonist 7-25 amino acids in length, wherein said ADM agonist comprises a fraction or the entirety of the amino acid sequence ADM(32-40).
- 11. The method of claim 10, wherein said agonist is 9-25 amino acids in length and comprises the amino acid sequence ADM(32-40).
- 12. The method of claim 10, wherein said ADM agonist is administered nasally or pulmonarily.
- 13. The method of claim 10, wherein said ADM agonist is in a sustained release formulation.
- 14. The method of claim 10, wherein said ADM agonist is administered parenterally.
- 15. The method of claim 10, wherein said ADM agonist is amidated at its carboxyl terminus.
- 16. The method of claim 10, wherein said patient suffers from osteoporosis.
- 17. The method of claim 11, wherein said patient suffers from osteoporosis.
- 18. A method of promoting bone growth in a subject at risk for developing a bone-associated disease, said method comprising administering to a subject in need thereof an ADM agonist 7-25 amino acids in length, wherein said ADM agonist comprises a fraction or the entirety of the amino acid sequence ADM(32-40).
- 19. The method of claim 18, wherein said ADM agonist is 9-25 amino acids in length and includes the amino acid sequence ADM(32-40).
- 20. The method of claim 18, wherein said ADM agonist is administered nasally or pulmonarily.
- 21. The method of claim 18, wherein said ADM agonist is in a sustained release formulation.
- 22. The method of claim 18, wherein said ADM agonist is administered parenterally.
- 23. The method of claim 18, wherein said ADM agonist is amidated at its carboxyl terminus.
- 24. The method of claim 18, wherein said subject is at risk for osteoporosis.
- 25. The method of claim 19, wherein said subject is at risk for osteoporosis.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Ser. No. 08/634,562, filed Apr. 18, 1996.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09280501 |
Mar 1999 |
US |
Child |
10228872 |
Aug 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08634562 |
Apr 1996 |
US |
Child |
09280501 |
Mar 1999 |
US |